Weight & Metabolic · Peptide Guide
The clinical trial numbers for GLP-1 peptides are genuinely impressive, 15% average weight loss on semaglutide, 20%+ on tirzepatide. These are real results from real trials. But they are…
Understanding the gap between clinical trial headlines and what you are likely to experience in practice, and what factors determine which side of that gap you land on, is one of the most useful things anyone considering peptide-assisted weight loss can do before starting. This guide gives you that honest picture.
Clinical trials are designed to show what a drug can do under optimal conditions. They select patients carefully, exclude many comorbidities, provide intensive monitoring and dietitian support, require strict medication adherence, and track participants at regular intervals throughout. These conditions maximise adherence and outcomes, and they are not what most patients experience in routine clinical practice.
Real-world data consistently shows lower average weight loss than clinical trials, but the gap is smaller than it might seem, and it narrows significantly when patients are supported by structured programmes. The most important driver of the gap is not medication effectiveness, it is dose achievement and persistence.[1]
Semaglutide weight loss−14.9% at 68 wks
Tirzepatide weight loss−22.5% at 72 wks
Max dose reachedProtocol-mandated
Monitoring frequencyRegular; often monthly
Dietitian supportProvided in most trials
Discontinuation rate~14–17% at 1 year
Semaglutide weight loss−9.4 to −14.1% at 12 months*
Tirzepatide weight loss−14.4 to −16.5% at 12 months*
Max dose reached23% (sema) / 28% (tirz) at full dose
Monitoring frequencyVariable; often less frequent
Dietitian supportLess consistent; programme-dependent
Discontinuation rate20–52% within 12 months
*Range reflects variation across real-world studies; persistent users in structured programmes approach trial-level results.
The critical insight from real-world data: patients who remain persistent on their medication and successfully titrate to therapeutic dose consistently achieve weight loss that approaches clinical trial levels. A 2025 analysis from Vanderbilt’s academic obesity clinic found that patients persistent at 12 months achieved a median weight loss of 14.4%, closely matching the STEP-1 trial result. The underperformers were disproportionately those who discontinued early or never reached optimal dose.[2]
Another limitation of clinical trial averages: they are means of a wide distribution. The “average” patient in a semaglutide trial lost 14.9% of body weight, but there is no single “average” patient. Behind that mean is a distribution ranging from minimal responders who lost less than 5% to exceptional responders who lost 30% or more.
In the STEP-1 trial for semaglutide, the full picture looked something like this:
<5% loss
Minimal response
~13%
5–14.9% loss
Moderate response
~31%
≥15% loss
Good response
~56%
≥20% loss
Excellent response
~35%
Note: Tiers overlap, ≥20% is a subset of ≥15%. Most patients respond meaningfully; minimal response is the minority outcome.
For tirzepatide, the response distribution is shifted upward, with approximately 57% of participants achieving ≥20% weight loss and 31.6% achieving ≥25% in the SURMOUNT-5 head-to-head trial. But the same spread exists: some patients lose far more than the average, some lose far less.[3]
This means that entering treatment expecting the average may leave you unprepared for either a better-than-average result (not uncommon) or a below-average one (also not uncommon and not a reason to conclude the treatment is failing). Understanding that you are one point in a distribution, not the average, is fundamental to setting realistic expectations.
Response to GLP-1 therapy is not random. Several factors consistently predict better or worse outcomes, and understanding them before you start can help calibrate your expectations and inform the design of your protocol.
High Impact
The strongest predictor of total weight loss is whether you reach and tolerate the maximum therapeutic dose. Only 23% of semaglutide users and 28% of tirzepatide users in real-world studies reached maximum dose. Those who do consistently achieve the best outcomes.
High Impact
Patients who remain on treatment without gaps or interruptions approach clinical trial results. Discontinuation, the largest single driver of real-world underperformance, is strongly associated with lower dose achievement and absence of structured clinical support.
High Impact
Non-diabetic patients consistently achieve greater weight loss on GLP-1 medications than those with type 2 diabetes, a pattern seen across all major trials and real-world studies. The metabolic environment of T2D limits the magnitude of GLP-1-mediated weight loss.
High Impact
Combining GLP-1 therapy with resistance training and adequate protein (1.6–2.2g/kg/day) produces significantly better body composition outcomes, preserving or increasing lean mass while maximising fat loss. Sedentary patients on poor protein intakes lose proportionally more muscle.
Moderate Impact
Women consistently achieve greater weight loss than men on GLP-1 medications across clinical trials and real-world studies. The SURMOUNT-5 head-to-head trial noted approximately 6% lower weight loss in men than women in both treatment groups.
Moderate Impact
Patients enrolled in structured programmes with dietitian coaching, regular monitoring, and behavioural support consistently outperform those receiving medication alone. A 2025 remote weight management study reported 17–22% weight loss, approaching trial levels, specifically because of combined medication and behavioural intervention.
Moderate Impact
Patients with higher starting BMI tend to lose more weight in absolute terms but show similar percentage outcomes. Those with the most excess weight typically have the most room for clinically meaningful improvement.
Moderate Impact
A post-hoc analysis of SURMOUNT-1 found that patients achieving ≥5% weight loss by week 12 went on to achieve significantly greater total weight loss by week 72. Early response at 12 weeks is a useful prognostic signal worth discussing with your clinician.
One of the most important and under-discussed aspects of real-world peptide therapy outcomes is how common discontinuation is, and how severely it affects outcomes. In clinical trials, discontinuation rates are 14–17% at one year. In real-world practice, the numbers are much higher.
A 2025 retrospective study of over 40,000 real-world GLP-1 users found that approximately 52–56% of patients had discontinued treatment by 12 months, with follow-up ended by discontinuation.[4] A Cleveland Clinic analysis of 2024 data found that 20.4% of patients discontinued early and 32.0% discontinued late, significantly higher than trial rates.
Why does this matter so much? Because weight loss on GLP-1 therapy is contingent on continued treatment. Patients who discontinued early in the Cleveland Clinic study had substantially lower odds of achieving ≥10% weight reduction at 12 months. The medication works by maintaining a sustained biological signal, when that signal is removed, the effect reverses.
| Reason for Discontinuation | Frequency | What Helps |
|---|---|---|
| Gastrointestinal side effects | Most common early reason, particularly weeks 1–8 | Slow titration; smaller meals; staying hydrated; anti-nausea strategies |
| Inadequate weight loss response | Common reason for stopping at 3–6 months | Dose optimisation; check whether maximum dose has been reached |
| Cost and insurance barriers | Major real-world factor, particularly in US without employer coverage | Manufacturer discount programmes; insurance appeals; telehealth platforms |
| Feeling “done” after initial loss | Common after plateau, when patients feel they’ve reached their goal | Clear long-term plan established before starting; clinician-guided de-escalation |
| Medication shortage / access issues | Has fluctuated significantly 2022–2025 | Relationships with multiple dispensing pharmacies; early refills when available |
~⅔
of lost weight regained within 12 months of stopping semaglutide (STEP 1 extension study)
52%
of real-world patients had discontinued GLP-1 therapy by 12 months
80%
of clinical trial-level outcomes maintained at 20 weeks in those who continued tirzepatide (SURMOUNT-4)
Weight regain after GLP-1 discontinuation is not a personal failure, it is the predictable pharmacological consequence of removing a sustained biological signal that was suppressing appetite and altering metabolic function. The body’s hunger and energy regulation systems return to their previous set point. This is why major clinical guidelines increasingly frame obesity as a chronic disease requiring long-term pharmacological management, not a condition to be treated with a short course of medication and then resolved.
The STEP 4 trial demonstrated this directly: patients who had achieved significant weight loss on semaglutide and then switched to placebo regained most of their weight within months, while those who continued treatment maintained their loss. SURMOUNT-4 showed similar findings for tirzepatide, those who continued at maintenance dose retained approximately 80% of their clinical trial weight loss. Those who stopped did not.[5]
The practical implication is not that peptide therapy should never be stopped, it is that the decision to stop should be made with a plan for what comes next. Sustainable dietary habits, exercise, and metabolic health established during treatment are the bridge to maintaining results after any planned de-escalation.
Based on the clinical evidence, here is a realistic expectation framework for someone starting GLP-1 therapy with good clinical support and genuine adherence:
The single most useful mindset shift
The patients who achieve the best long-term outcomes from peptide-assisted weight loss are those who treat the medication as a tool for establishing new metabolic habits, not as a treatment that does the work independently. The appetite suppression that GLP-1s provide creates an opportunity to build better eating patterns and exercise habits. Patients who use that window to make lasting lifestyle changes do better than those who treat it as a passive intervention.
It is worth being explicit about what clinically meaningful weight loss actually produces in health terms, because this reframes what “success” means. Clinical guidelines define clinically meaningful weight loss as 5–10% of body weight. At that level:
Even achieving 8–10% weight loss, at the lower end of real-world outcomes, produces clinically significant and health-meaningful results. The headline clinical trial numbers are remarkable, but they are not the threshold below which the medication “didn’t work.”
⚠️ Warning signs that expectations need recalibrating:
GLP-1 peptides produce genuinely impressive weight loss results, in clinical trials, and in the real world for patients who persist, reach therapeutic dose, and combine the medication with appropriate lifestyle support. The gap between the headline numbers and real-world averages is real but bridgeable, and the biggest driver of that gap is discontinuation rather than medication ineffectiveness.
The most important expectations to set correctly are: the time it takes to reach peak efficacy (months, not weeks), the variability of individual response (you are not the average), the consequences of stopping (substantial regain, quickly), and the role of lifestyle as an amplifier rather than an optional extra.
Patients who enter this class of therapy with realistic, evidence-based expectations, and with a long-term plan rather than a short-term goal, consistently achieve the best outcomes. That framing is not pessimistic. It is the context that makes the impressive clinical data translate into durable, meaningful results.
Our free quiz takes 3 minutes and helps you understand your options before speaking to a clinician.